Drug
Gadoterate meglumine clinical trials
Also written Dotarem.
- studies test it
- 15
- open now
- 3
- in phase 3
- 6
- first study started
- 2008
Keep track of what changes. Save the gadoterate meglumine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
14 studies that test it; most in 2009 (5); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 2
- Phase 2
- 1
- Phase 3
- 6
- Phase 4
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 3
Guerbet (12) · University of Chicago (1) · Columbia University (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Gadobutrol (1) · Sulfur Hexafluoride (1) · Florbetapir (1) · MK-6240 (1) · Gadopiclenol (1) · CBP-8 gallium GA-68 (1)
Studies
Open first, then newest update. How each study uses gadoterate meglumine is read from its arms, and is right about nine times in ten.
Testing it · 15
- Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular DiseaseRecruitingPhase 3GuerbetNCT07348640Written as Gadoterate meglumine (Dotarem)
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and TauNot yet recruitingPhase 1Columbia UniversityNCT06600880Written as Dotarem
- Collagen-targeted PET Imaging for Early Interstitial Lung DiseaseRecruitingPhase 2Massachusetts General HospitalNCT05417776Written as Dotarem
- Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)CompletedEarly Phase 1University of ChicagoNCT04341129Written as Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
- DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCCTerminatedPhase 4GuerbetNCT01806740Written as Gadoterate meglumine
- Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) LesionsCompletedPhase 3GuerbetNCT01211873Written as Dotarem (gadoterate meglumine)
- DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 YearsCompletedPhase 4GuerbetNCT02411201Written as DOTAREM
- Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain TumorsCompletedPhase 4GuerbetNCT02034708Written as Dotarem®
- Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)CompletedPhase 3GuerbetNCT01012674Written as Dotarem
- Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)CompletedPhase 3GuerbetNCT01010932Written as Dotarem
- Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)TerminatedPhase 3GuerbetNCT00980681Written as Dotarem
- Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)TerminatedPhase 3GuerbetNCT00845702Written as Gadoterate meglumine (Dotarem)
- Safety and Dialysability of Dotarem® in Dialysed PatientsCompletedPhase 1GuerbetNCT01449266Written as Dotarem® IV injection at 0.1 mmol/kg
- Renal Safety Evaluation After Dotarem®-Enhanced MRICompletedPhase 4GuerbetNCT00650845Written as Dotarem®-enhanced MRI
- Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial DiseaseCompletedPhase 4GuerbetNCT01026389Written as Dotarem
Given in every arm · 1 — gadoterate meglumine is usual care beside what is tested
As the comparator · 2 — what is tested is compared with gadoterate meglumine
Codes
What other systems call gadoterate meglumine · ClinicalTrials.gg INT003606
- MeSH (NLM) C072417gadoterate meglumineConfirmed NLM, Wikidata
- UNII (FDA) L0ND3981AGGADOTERATE MEGLUMINEConfirmed FDA, NLM, Wikidata
- RxNorm 1421151Confirmed FDA, Wikidata
- Wikidata Q27144071gadoterate meglumineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C80124Gadoterate MeglumineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C072417 | gadoterate meglumine | Confirmed NLM, Wikidata |
| UNII (FDA) | L0ND3981AG | GADOTERATE MEGLUMINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1421151 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27144071 | gadoterate meglumine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C80124 | Gadoterate Meglumine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.